Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin versus metformin for cognition in type 2 diabetes with early Alzheimer's disease
ChiCTR2200058913Phase 4Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of canagliflozin and metformin in type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: iADRS score. Planned start May 2022; status: not yet recruiting.
02
Drugs
canagliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR2200058913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058913.